MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 14, 2007; DOI: 10.1124/mol.107.036459


0026-895X/07/7203-563-571$20.00
Mol Pharmacol 72:563-571, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.036459v1
72/3/563    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huyet, J.
Right arrow Articles by Rafestin-Oblin, M.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huyet, J.
Right arrow Articles by Rafestin-Oblin, M.-E.

Structural Basis of Spirolactone Recognition by the Mineralocorticoid Receptor

Jessica Huyet, Grégory M. Pinon, Michel R. Fay, Jérôme Fagart, and Marie-Edith Rafestin-Oblin

Institut National de la Santé et de la Recherche Médicale, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3, BP 416, Paris, France; and Université Paris 7 Denis Diderot, site Bichat, BP 416, Paris, France

Spirolactones are potent antagonists of the mineralocorticoid receptor (MR), a ligand-induced transcription factor belonging to the nuclear receptor superfamily. Spirolactones are synthetic molecules characterized by the presence of a C17 {gamma}-lactone, which is responsible for their antagonist character. They harbor various substituents at several positions of the steroid skeleton that modulate their potency in ways that remain to be determined. This is particularly obvious for C7 substituents. The instability of antagonist-MR complexes makes them difficult to crystallize. We took advantage of the S810L activating mutation in MR (MRS810L), which increases the stability of ligand-MR complexes to crystallize the ligand-binding domain (LBD) of MRS810L associated with 7{alpha}-acetylthio-17beta-hydroxy-3-oxopregn-4-en-21-carboxylic acid {gamma}-lactone (SC9420), a spirolactone with a C7 thioacetyl group. The crystal structure makes it possible to identify the contacts between SC9420 and MR and to elucidate the role of Met852 in the mode of accommodation of the C7 substituent of SC9420. The transactivation activities of MRS810L/Q776A, MRS810L/R817A, and MRS810L/N770A reveal that the contacts between SC9420 and the Gln776 and Arg817 residues are crucial to maintaining MRS810L in its active state, whereas the contact between SC9420 and the Asn770 residue contributes only to the high affinity of SC9420 for MR. Moreover, docking experiments with other C7-substituted spirolactones revealed that the MRS810L-activating potency of spirolactones is linked to the ability of their C7 substituent to be accommodated in LBD. It is remarkable that the MRS810L-activating and MRWT-inactivating potencies of the C7-substituted spirolactones follow the same order, suggesting that the C7 substituent is accommodated in the same way in MRS810L and MRWT. Thus, the MRS810L structure may provide a powerful tool for designing new, more effective, MR antagonists.


Received March 27, 2007; accepted June 12, 2007

Address correspondence to: Marie-Edith Rafestin-Oblin, INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon, 16, rue Henri Huchard, BP416, 75870 Paris, France. E-mail: oblin{at}bichat.inserm.fr







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics